Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02317302 · ClinicalTrials.gov registry record · Phase 1
FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02317302 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 48 participants.
The verdict
NCT02317302, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
In this study, 50 evaluable patients will undergo one FDG-PET study during their chemoradiation, in addition to the standard of care pretreatment and 3-month post-treatment clinical FDG-PET/CT or FDG-PET/MR scans. From all FDG-PET studies, tumor volume, SUVmax, FDGhetero, and texture maps will be obtained. Evaluating the changes in tumor SUVmax and heterogeneity during treatment will aid in better understanding the role of these biological parameters in inadequate response to chemoradiation. Other researchers, using MRI imaging, have evaluated changes in the cervical tumor volume during treatment. The investigators expect there will be variation in how cervical tumors shrink and change during chemoradiation and therefore we are going to use multiple measures in addition to tumor volume to evaluate cervical tumor metabolic heterogeneity. Being able to predict at diagnosis the patients who are at higher risk for persistent disease following chemoradiation would allow for future studies where these high risk patients could be specifically targeted with more aggressive therapy.
Interventions
- DEVICE FDG-PET/MR
- DEVICE FDG-PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-06-28 |
| Est. Completion | 2020-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02317302
The ClinicalTrials.gov registry entry for NCT02317302 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FDG-PET/MR is the first listed.
NCT02317302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02317302 about?
NCT02317302 is a clinical study titled "FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer". In this study, 50 evaluable patients will undergo one FDG-PET study during their chemoradiation, in addition to the standard of care pretreatment and 3-month post-treatment clinical FDG-PET/CT or FDG-PET/MR scans. From all FDG-PET studies, tumor volume, SUVmax, FDGhetero, and texture maps will be ob...
What is the current status of trial NCT02317302?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-06-28. Estimated completion is 2020-06-02.
What interventions are being tested in trial NCT02317302?
The interventions under investigation include: FDG-PET/MR (DEVICE), FDG-PET/CT (DEVICE).
Who is sponsoring clinical trial NCT02317302?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.